Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1AKNI)

• Drug Name: TAK-252 Drug Info
• Synonyms: SL-279252

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM1AKNI

Molecule-Related Drug Atlas

Drug(s) Targeting OX40L receptor (CD134)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rocatinlimab	DMG1U5K	Atopic dermatitis	EA80	Phase 3	[3]
GBR 830	DM2VO9T	Atopic dermatitis	EA80	Phase 2	[4]
PF-04518600	DMZMUIL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
INCAGN01949	DMK7OHI	Advanced malignancy	2A00-2F9Z	Phase 2	[6]
INCAGN1949	DM7OE3X	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
Anti-OX40 mab	DMFZ52G	Prostate cancer	2C82.0	Phase 1	[8]
MEDI0562	DMYVBU6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
BGB-A445	DMQMEDH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
YH002	DMWVRHD	Aggressive cancer	2A00-2F9Z	Phase 1	[10]
YH006	DMRECC2	Aggressive cancer	2A00-2F9Z	Investigative	[11]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[12]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[13]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[14]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[15]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[16]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[17]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[18]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[19]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[20]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
OX40L receptor (CD134)	TTL31H0	TNR4_HUMAN	Agonist	[2]
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Agonist	[2]

References

• [1] Clinical pipeline report, company report or official report of Takeda.
• [2] Clinical pipeline report, company report or official report of Shattuck Labs.
• [3] An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023 Jan 21;401(10372):204-214.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1873).
• [9] Clinical pipeline report, company report or official report of BeiGene.
• [10] Clinical pipeline report, company report or official report of Biocytogen
• [11] Clinical pipeline report, company report or official report of Biocytogen
• [12] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [14] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [15] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [17] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [18] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [19] National Cancer Institute Drug Dictionary (drug id 740856).
• [20] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [21] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.